- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
- Interventions
- TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (givastomig), durvalumab, chemotherapy
- Drug
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • Layfayette, Indiana + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 1,775
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Eosinophilic Esophagitis
- Interventions
- EUR-1100, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 3 more
- Conditions
- Barrett's Esophagus
- Interventions
- Not listed
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Kenner, Louisiana
- Conditions
- Dysplastic Barrett's Esophagus, Radiofrequency Ablation, Barrett Esophagus
- Interventions
- Radiofrequency ablation alone
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer
- Interventions
- Topotecan and pegylated doxorubicin
- Drug
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Fatigue, Lung Cancer, Lymphoma, Ovarian Cancer, Prostate Cancer
- Interventions
- exercise intervention, complementary or alternative medicine procedure, fatigue assessment and management, physical therapy
- Behavioral · Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- rabeprazole sodium
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 25
- States / cities
- Longmont, Colorado • Fort Lauderdale, Florida • New Port Richey, Florida + 21 more
- Conditions
- Dyspepsia, GERD, Acid Reflux
- Interventions
- Intravenous Famotidine, Oral Maalox/ Mylanta
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Interventions
- Nal-IRI, Oxaliplatin, 5-FU, Trastuzumab, Pembrolizumab, Nivolumab
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Esophageal Cancer
- Interventions
- ZD1839
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Barrett Esophagus, Esophageal Cancer
- Interventions
- metformin hydrochloride, placebo
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Hines, Illinois • Rochester, Minnesota • Cleveland, Ohio + 1 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Vonoprazan, Placebo
- Drug
- Lead sponsor
- Phathom Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 41
- States / cities
- Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more
- Conditions
- Barrett Esophagus, Esophageal Adenocarcinoma, Gastroesophageal Reflux
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
- Interventions
- MDX2001
- Drug
- Lead sponsor
- ModeX Therapeutics, An OPKO Health Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7
- Interventions
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Radiation · Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Achalasia
- Interventions
- Per oral endolumenal myotomy
- Procedure
- Lead sponsor
- The Oregon Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Esophageal Cancer, Gastroesophageal Cancer
- Interventions
- Oxaliplatin, Irinotecan
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
- Interventions
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cisplatin, paclitaxel, adjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 59 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Omeprazole (suspension), Lifestyle Modification
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 0 Years to 4 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Esophageal Cancer, Malignant Neoplasm of Cardio-esophageal Junction of Stomach
- Interventions
- Azacitidine, Oxaliplatin, Epirubicin, Capecitabine
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Sucralfate, Intraluminal Impedance, Intraluminal Impedance
- Drug · Procedure · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose, Placebo
- Biological · Other
- Lead sponsor
- Uniquity One (UNI)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 38
- States / cities
- Dothan, Alabama • Glendale, Arizona • Peoria, Arizona + 35 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Partial enteral nutrition (PEN) with dairy elimination, Dairy elimination alone
- Other
- Lead sponsor
- Kate Farms Inc
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington